ClinicalTrials.gg
CompletedNCT02138162Updated May 14, 2014

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

A Phase 1 interventional study of enzalutamide in Severe Hepatic Impairment and Normal Hepatic Function, sponsored by Astellas Pharma Europe B.V.. Completed at 1 site in Bulgaria. Open to male participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-14.

Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 69 Years
Sex
Male
01

Study summary

The influence of severely diminished liver function on the metabolism, safety, and tolerability of a single oral dose of enzalutamide in a group of 8 men. The results are compared to the data gained from 8 age- and BMI-matched men with normal liver function.

Read the detailed description

Screening takes place between Day -22 and Day -2, and subjects are admitted to the clinic on Day -1. Each subject receives a single oral dose of enzalutamide on Day 1, under fasted conditions. They are discharged on Day 7; ambulant visits take place until Day 50. An End of Study Visit (ESV) occurs 7-10 days after the last PK sampling or early withdrawal.

Full PK profiles are obtained for enzalutamide, metabolite 1 of enzalutamide (M1) and metabolite 2 of enzalutamide (M2) up to 1176 hours (Day 50) after administration.

Safety assessments are performed throughout the study. For subjects with severe hepatic impairment, additional Child-Pugh classification and laboratory safety tests (including liver function tests) are performed regularly after administration.

02

Conditions studied

  • Severe Hepatic Impairment
  • Normal Hepatic Function

Keywords

  • Phase 1
  • Pharmacokinetics
  • Safety
  • Severe hepatic impairment
  • Enzalutamide
03

In context

Lead sponsor

Astellas Pharma Europe B.V. is the lead sponsor of 94 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subject and their female spouse/partners who are of must be using highly effective consisting of two forms of birth control starting at Screening and continue throughout the study period and for 90 days after the final study drug administration.
  • Male subject must not donate sperm starting at Screening and throughout the study period and for 90 days after the final study drug administration.
  • Subject has a (BMI) range of 18.5 - 34.0 kg/m2 inclusive. The subject weighs at least 50 kg [at Screening].

Inclusion Criteria:Subjects with severe hepatic impairment must also meet the following inclusion criteria:

  • Subject has a classification Class C (severe, 10 to 15 points).

Inclusion Criteria: For Healthy Subjects Only:

  • Age- and BMI-matched to subjects with severe liver hepatic impairment.

Exclusion criteria

Exclusion Criteria:

  • Subject has known or suspected to enzalutamide, or any components of the formulation used.
  • Subject has history of seizure or any condition that may predispose to seizure. Also history of loss of consciousness or within 12 months of enrollment (Day 1 visit).
  • Subject has used grapefruit (or grapefruit containing products) or marmalade in the week prior to admission to the clinical unit (Day -1), as reported by the subject.

Exclusion Criteria: For Healthy Subjects Only:

  • Subject has any of the liver function tests above the .

Exclusion Criteria: Subjects with severe hepatic impairment must also not have any of the following characteristics:

  • Subject has fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period.
  • Subject has surgical porto-systemic shunts, including TIPSS (Trans-jugular intrahepatic portosystemic shunt).
  • Subject has presence of severe hepatic encephalopathy (grade > 2).
  • Subject has advanced ascites.
  • Subject has esophageal variceal bleeding in the medical history (within 6 months before Day -1).
  • Subject has level below 40x109 /L and /or below 90 g/L.
  • Subject has significant renal dysfunction ( below 50 mL/min, estimated according to the method of Modification of Diet in Renal Disease () formula).
  • Subject has had previous liver transplantation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    1:Single dose of enzalutamide in hepatically impaired subjects

    Single dose of enzalutamide

    Drug: enzalutamide

  • Experimental
    2:Single dose of enzalutamide in healthy subjects

    Single dose of enzalutamide

    Drug: enzalutamide

Interventions

  • oral

    Also known as: ASP9785,, MDV3100,, Xtandi

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of enzalutamide after a single oral dose

    area under the plasma concentration - time curve (AUC) extrapolated to infinity (AUC0-inf)

    Time frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50

  2. PK of enzalutamide after a single oral dose

    maximum concentration (observed) (Cmax)

    Time frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50

  3. PK of enzalutamide plus N-desmethyl enzalutamide (M2) after a single oral dose

    area under the plasma concentration - time curve (AUC) extrapolated to infinity (AUC0-inf)

    Time frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50

  4. PK of enzalutamide plus N-desmethyl enzalutamide (M2) after a single oral dose

    maximum concentration (observed) (Cmax)

    Time frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50

Secondary outcomes

  1. PK of enzalutamide, M1, M2 and the sum of enzalutamide plus N-desmethyl enzalutamide (M2)

    Cmax and AUC0-inf (M1, M2 only), time to attain Cmax (tmax), AUC up to last quantifiable concentration (AUC0-last), apparent terminal elimination half life (t1/2), apparent volume of distribution during the terminal phase after extra vascular dosing (Vz/F), apparent total body clearance after extra vascular dosing (CL/F) (parent compound only), Metabolite-to-Parent Ratio (MPR), percent extrapolated for AUC0-inf (%AUC)

    Time frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50

  2. Additional pharmacokinetic variables for enzalutamide, and, as appropriate, for M1 and M2, based upon unbound plasma concentrations

    Unbound Cmax (Cmax,u), unbound AUC0-inf (AUC0-inf,u), and unbound AUC0-last (AUC0-last,u). Unbound CL/F (CLu/F) and unbound Vz/F (Vz,u/F) (parent only)

    Time frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50

07

Study locations

1 site
  • Comac Medical Ltd.
    Sofia, 1612, Bulgaria
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2014
First posted
May 14, 2014
Start
Aug 2013
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
May 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02138162
Collaborators
Medivation, Inc.
Responsible party
Sponsor
First posted
May 14, 2014
Start date
Aug 2013
Primary completion
Mar 2014
Completion
Mar 2014
Last update
May 14, 2014

Study contacts

Medical Monitor
study director · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion